ScholarIQanswers from OpenAlex & ORCID
Nobukazu Fujimoto
ResearcherPublications, citations & collaboration network
Nobukazu Fujimoto is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nobukazu Fujimoto have?
ScholarIQindexed works
Nobukazu Fujimoto has 246 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nobukazu Fujimoto have?
ScholarIQcitation count
Nobukazu Fujimoto has 5,087 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nobukazu Fujimoto?
ScholarIQh-index
Nobukazu Fujimoto has an h-index of 34 in OpenAlex.
What is the i10-index of Nobukazu Fujimoto?
ScholarIQi10-index
Nobukazu Fujimoto has an i10-index of 83 in OpenAlex.
What is the ORCID of Nobukazu Fujimoto?
ScholarIQorcid
The ORCID for Nobukazu Fujimoto is on the source record.
What is the OpenAlex record for Nobukazu Fujimoto?
ScholarIQopenalex
The OpenAlex for Nobukazu Fujimoto is on the source record.
What are the most-cited papers on Nobukazu Fujimoto?
ScholarIQmost cited works
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz M. Kowalski, Jerónimo Rafael Rodríguez‐Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, Thomas Talbot, I. Monnet, Sandrine Hiret, P. Baas, Anna K. Nowak, Nobukazu Fujimoto, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, X. Zhang, Nan Hu, David Balli, Thomas Spires, Gérard Zalcman
Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)
Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai, Fumio Imamura, Satoshi Oizumi, Toshiaki Takahashi, Mitsuhiro Takenoyama, Hiroshi Tanaka, Jun Hirano, Yoshinobu Namba, Yuichiro Ohe
Identification of Epigenetic Aberrant Promoter Methylation in Serum DNA Is Useful for Early Detection of Lung Cancer
Keiichi Fujiwara, Nobukazu Fujimoto, Masahiro Tabata, Kenji Nishii, Keitaro Matsuo, Katsuyuki Hotta, Toshiyuki Kozuki, Motoi Aoe, Katsuyuki Kiura, Hiroshi Ueoka, Mitsune Tanimoto
High Expression of Ligands for Chemokine Receptor CXCR2 in Alveolar Epithelial Neoplasia Induced by Oncogenic Kras
Marie Wislez, Nobukazu Fujimoto, Julie Izzo, Amy E. Hanna, Dianna D. Cody, Robert R. Langley, Hongli Tang, Marie D. Burdick, Mitsuo Sato, John D. Minna, Li Mao, Ignacio I. Wistuba, Robert M. Strieter, Jonathan M. Kurie